Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TelyRx HoldingsTSX:TELY +13.04%12 5-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus rates TSX:TELY with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 535 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 186915.7% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
TelyRx Holdings does not have enough data to calculate 5-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TelyRx Holdings 5-Year ROIIC % Related Terms
TelyRx Holdings 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TelyRx Holdings's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, TelyRx Holdings's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TelyRx Holdings 5-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TelyRx Holdings's 5-Year ROIIC % falls into.
TelyRx Holdings's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -6.572 (Dec. 2025) - (Dec. 2020) )
/
( 18.894 (Dec. 2025) - (Dec. 2020) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TelyRx Holdings (TSX:TELY) has a 5-Year ROIIC % of 0.00 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #999999 out of 535 companies in the Healthcare Providers & Services industry.
Is TelyRx Holdings' 5-Year ROIIC % too high?
TelyRx Holdings' current 5-Year ROIIC % is 0.00. Based on the distribution chart, TelyRx Holdings ranks #999999 out of 535 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' 5-Year ROIIC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #999999 out of 535 companies for 5-Year ROIIC %. This places TelyRx Holdings in the lower half of its industry. The industry median 5-Year ROIIC % is 3.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Healthcare Providers & Services company?
The median 5-Year ROIIC % among Healthcare Providers & Services companies is 3.44, based on 535 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median 5-Year ROIIC % is 3.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current 5-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TSX:TELY) has a current 5-Year ROIIC % of 0.00. The current 5-Year ROIIC % is 0.00. TelyRx Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For TelyRx Holdings (TSX:TELY), the current 5-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score
Get the complete analysis for TSX:TELY
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:TELY has been successfully added to your 
